NOV 24, 2020 12:20 PM PST

MMR Vaccine Shows Promise Against COVID-19

WRITTEN BY: Annie Lennon

Researchers have found that a vaccine used for mumps, measles, and rubella (MMR) may be effective in protecting against more severe symptoms from COVID-19. 

The study comes after findings from a team at Mexico Sur in Mexico City suggesting that the MMR vaccine may be able to reduce symptom severity in those with COVID-19. In this paper, published in September 2020, researchers observed that among 255 people vaccinated with the MMR vaccine since the beginning of the COVID-19 pandemic, 36 were later infected with the virus and had a 'remarkably mild course'. 

To follow up on this work, researchers led by Jeffrey E. Gold, president of Rescue Me/ World Organization, an animal shelter in Watkinsville, GA, set up a study to investigate the connection between the MMR vaccine and the severity of symptoms from COVID-19 infection in recovered patients. 

For the study, they recruited 80 people and put them into two groups. A group of 50 had MMR antibodies from the MMR II vaccine, while a comparison group of 30 people had no record of MMR II vaccinations, nor any history of MMR antibodies from infections with measles, mumps, or rubella. 

All in all, the researchers found that those with antibodies for mumps had significantly less severe COVID-19 symptoms than those in the comparison group. In particular, they found that those who were asymptomatic with COVID-19 tended to have higher levels of mumps antibodies. In turn, they found a significant inverse correlation between the number of mumps antibodies each person had and the severity of their symptoms from COVID-19.  

"This [the findings] adds to other associations demonstrating that the MMR vaccine may be protective against COVID-19." says Jeffrey E. Gold, lead author of the study. "It also may explain why children have a much lower COVID-19 case rate than adults, as well as a much lower death rate. The majority of children get their first MMR vaccination around 12 to 15 months of age and a second one from 4 to 6 years of age."

 

Sources: Medical NewsmBioAllergy

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
JUL 05, 2021
Drug Discovery & Development
ADHD Drug Reduces Daydreaming, Fatigue and Boredom
JUL 05, 2021
ADHD Drug Reduces Daydreaming, Fatigue and Boredom
Researchers led by New York University have found that a stimulant drug may be able to treat persistent daydreaming, fat ...
JUL 15, 2021
Drug Discovery & Development
The genomics of high blood pressure - a road to the future of treatment
JUL 15, 2021
The genomics of high blood pressure - a road to the future of treatment
The human heart begins to beat in utero in the early weeks of development and continues throughout life. In an average l ...
AUG 18, 2021
Neuroscience
Histamine Regulates Serotonin Levels in Depression
AUG 18, 2021
Histamine Regulates Serotonin Levels in Depression
Heightened histamine levels from inflammation inhibit the effects of the mood-regulating neurotransmitter serotonin in t ...
AUG 20, 2021
Cannabis Sciences
Teenage Cannabis Use Linked to Preterm Births in Adulthood
AUG 20, 2021
Teenage Cannabis Use Linked to Preterm Births in Adulthood
People who heavily used cannabis in their teens are more likely to have premature babies than those who did not use the ...
SEP 07, 2021
Drug Discovery & Development
A giant step in treating growth disorders in children.
SEP 07, 2021
A giant step in treating growth disorders in children.
Hormone production and release is important in individuals of all ages but is especially important for children as hormo ...
SEP 07, 2021
Health & Medicine
Vaccines- a Long History of Cost-Benefit Analysis
SEP 07, 2021
Vaccines- a Long History of Cost-Benefit Analysis
Vaccination and new treatments for diseases have remained topics of skepticism since their inception. When it came to an ...
Loading Comments...